Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Ares Trading S.A. is managing 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are highly distributed, involving 7 distinct examiners across 7 distinct art units. This indicates a very broad and diverse range of research and development efforts within the sector.
The busiest examiner, TAYONG, HELENE E, is responsible for 1 pending office action. Because each of the 7 pending office actions is assigned to a different examiner and a different art unit, the company faces a broad prosecution landscape. This requires individual strategies for 7 separate points of contact at the patent office.
Managing 7 pending office actions across 7 distinct art units requires a sophisticated approach to patent strategy. The company must navigate the specific requirements of 7 distinct examiners, which may involve 7 different examination styles. This high level of activity in the Biotechnology & Pharmaceuticals area indicates a significant and ongoing investment in protecting its intellectual property across many technical silos.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (43%) |
| §103 only | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYONG, HELENE E | 1 | 89.1% | +14.9% |
| BERA, HENA RAKESHKUMAR | 1 | — | — |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
| RANDALL, JR., KELVIN L | 1 | 44.8% | +16.3% |
| ZEMAN, MARY K | 1 | 59.0% | +34.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18676669 | COMMUNICATION APPARATUS FOR USE WITH ELECTRONIC COMMUNICATION ELEMENT, ELECTRONIC COMMUNICATION ELEMENT AND USES THEREOF | TAYONG, HELENE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | YOUNGBLOOD, WILLIAM JUSTIN | 34d |
| 18283939 | METHOD FOR GLYCOSYLATION PROFILING TO DESCRIBE FUNCTIONAL CHARACTERISTICS OF A BIOLOGIC MOLECULE | BERA, HENA RAKESHKUMAR | — |
| 18280340 | IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS | LEE, YIE CHIA | — |
| 18251534 | Combination Treatment of Cancer | D' AMBROSIO, THEA | — |
| 17968167 | METHOD FOR DETERMINING CELL CLONALITY | ZEMAN, MARY K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | YOUNGBLOOD, WILLIAM JUSTIN | 34d |
| 18676669 | COMMUNICATION APPARATUS FOR USE WITH ELECTRONIC COMMUNICATION ELEMENT, ELECTRONIC COMMUNICATION ELEMENT AND USES THEREOF | TAYONG, HELENE E | — |
| 18280340 | IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS | LEE, YIE CHIA | — |
| 18251534 | Combination Treatment of Cancer | D' AMBROSIO, THEA | — |
| 18016110 | DISPENSING CUP | RANDALL, JR., KELVIN L | — |
| 17968167 | METHOD FOR DETERMINING CELL CLONALITY | ZEMAN, MARY K | — |
| Art Unit | Apps |
|---|---|
| 2631 | 1 |
| 1678 | 1 |
| 1644 | 1 |
| 1654 | 1 |
| 1629 | 1 |
| 3651 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18676669 | COMMUNICATION APPARATUS FOR USE WITH ELECTRONIC COMMUNICATION ELEMENT, ELECTRONIC COMMUNICATION ELEMENT AND USES THEREOF | TAYONG, HELENE E | 2631 | §103 | Non-Final OA | — | Pending | May 29, 2024 |
| 18283939 | METHOD FOR GLYCOSYLATION PROFILING TO DESCRIBE FUNCTIONAL CHARACTERISTICS OF A BIOLOGIC MOLECULE | BERA, HENA RAKESHKUMAR | 1678 | §101§103 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18280340 | IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS | LEE, YIE CHIA | 1644 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18251534 | Combination Treatment of Cancer | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §103§112 | Final Rejection | 34d | Pending | Feb 24, 2023 |
| 18016110 | DISPENSING CUP | RANDALL, JR., KELVIN L | 3651 | §103 | Final Rejection | — | Pending | Jan 13, 2023 |
| 17968167 | METHOD FOR DETERMINING CELL CLONALITY | ZEMAN, MARY K | 1672 | §101§102§112Other | Non-Final OA | — | Pending | Oct 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial